公开(公告)号：US20220213072A1

公开(公告)日：2022-07-07

申请号：US17546207

申请日：2021-12-09

Applicant: Pfizer Inc.

Inventor： Andrew John Bessire ,  David James Edmonds ,  David Andrew Griffith ,  Amit Sumant Kalgutkar ,  Timothy Frank Ryder

IPC: C07D405/14 ,  C07D401/14

Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.

公开(公告)号：US20240391908A1

公开(公告)日：2024-11-28

申请号：US18789977

申请日：2024-07-31

Applicant: Pfizer Inc.

Inventor： Andrew John Bessire ,  David James Edmonds ,  David Andrew Griffith ,  Amit Sumant Kalgutkar ,  Timothy Frank Ryder

IPC: C07D405/14 ,  A61K45/06 ,  C07D401/14

Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.

公开(公告)号：US12065434B2

公开(公告)日：2024-08-20

申请号：US17546207

申请日：2021-12-09

Applicant: Pfizer Inc.

Inventor： Andrew John Bessire ,  David James Edmonds ,  David Andrew Griffith ,  Amit Sumant Kalgutkar ,  Timothy Frank Ryder

IPC: C07D405/14 ,  A61K45/06 ,  C07D401/14

CPC classification number: C07D405/14 ,  C07D401/14 ,  A61K45/06

Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.